参考文献/References:
[1]中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版)[J].中华肝脏病杂志,2018,26(3):195-203.[2]Eslam M,Newsome PN,Sarin SK,et al.A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J].J Hepatol,2020,73(1):202-209.[3]Dongiovanni P,Crudele A,Panera N,et al.beta-Klotho gene variation is associated with liver damage in children with NAFLD[J].J Hepatol,2020,72(3):411-419.[4]Jain MR,Giri SR,Bhoi B,et al.Dual PPARalpha/gamma agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models[J].Liver Int,2018,38(6):1084-1094.[5]Maher JJ,Schattenberg JM.Nonalcoholic Fatty Liver Disease in 2020-ScienceDirect[J].Gastroenterology,2020,158(7):1849-1850.[6]Younossi Z,Tacke F,Arrese M,et al.Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis[J].Hepatology (Baltimore, Md.),2019,69(6):2672-2682.[7]金玉,武晓旭,李秋娟,等.非酒精性脂肪性肝病流行现状调查[J].人民军医,2021,64(5):425-428.[8]Townsend SA,Newsome PN.Non-alcoholic fatty liver disease in 2016[J].British Medical Bulletin,2016,119(1):143-156.[9]吴仪伟,武攸,崔晓艳,等.PLR、NLR与T2DM合并代谢相关脂肪性肝病肝纤维化的关系[J].临床与病理杂志,2022,42(7):1615-1621.[10]Estes C,Anstee QM,Arias-Loste MT,et al.Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J].J Hepatol,2018,69(4):896-904.[11]Zhang Y,Proenca R,Maffei M,et al.Positional cloning of the mouse obese gene and its human homologue[J].Nature,1994,372(6505):425-432.[12]Lin TC,Huang KW,Liu CW,et al.Leptin signaling axis specifically associates with clinical prognosis and is multifunctional in regulating cancer progression[J].Oncotarget,2018,9(24):17210-17219.[13]Khalafi M,Symonds ME.The impact of high-intensity interval training on inflammatory markers in metabolic disorders: A meta-analysis[J].Scand J Med Sci Sports,2020,30(11):2020-2036.[14]Komorizono Y,Hosoyamada K,Imamura N,et al.Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes:An analysis of the J-LINK study[J].Diabetes Obes Metab,2021,23(3):832-837.[15]Mirhafez SR,Farimani AR,Dehhabe M,et al.Effect of Phytosomal Curcumin on Circulating Levels of Adiponectin and Leptin in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial[J].J Gastrointestin Liver Dis,2019,28:183-189.[16]Navekar R,Rafraf M,Ghaffari A,et al.Turmeric Supplementation Improves Serum Glucose Indices and Leptin Levels in Patients with Nonalcoholic Fatty Liver Diseases[J].J Am Coll Nutr,2017,36(4):261-267.[17]Pour FK,Aryaeian N,Mokhtare M,et al.The effect of saffron supplementation on some inflammatory and oxidative markers, leptin, adiponectin, and body composition in patients with nonalcoholic fatty liver disease: A double-blind randomized clinical trial[J].Phytother Res,2020,34(12):3367-3378.[18]Lonardo A,Nascimbeni F,Maurantonio M,et al.Nonalcoholic fatty liver disease: Evolving paradigms[J].World J Gastroenterol,2017,23(36):6571-6592.[19]Polyzos SA,Aronis KN,Kountouras J,et al.Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis[J].Diabetologia,2016,59(1):30-43.[20]Zhang QZ,Liu YL,Wang YR,et al.Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease[J].Exp Ther Med,2017,14(3):2689-2694.[21]Scherer PE,Williams S,Fogliano M,et al.A novel serum protein similar to C1q, produced exclusively in adipocytes[J].J Biol Chem,1995,270(45):26746-26749.[22]Yamauchi T,Kadowaki T.Adipocytokines[J].Nihon Rinsho,2013,71(2):251-256.[23]Pal CS,Sanyal S,Chattopadhyay N.Adiponectin signaling and its role in bone metabolism[J].Cytokine,2018,112:116-131.[24]Xie X,Yan D,Li H,et al.Enhancement of Adiponectin Ameliorates Nonalcoholic Fatty Liver Disease via Inhibition of FoxO1 in Type I Diabetic Rats[J].J Diabetes Res,2018,2018:6254340.[25]Manieri E, Herrera-Melle L,Mora A,et al.Adiponectin accounts for gender differences in hepatocellular carcinoma incidence[J]. J Exp Med, 2019,216(5):1108-1119.[26]李盛,朱求实.外源性脂联素对大鼠非酒精性脂肪肝病影响的研究[J].新疆医科大学学报,2017,40(10):1322-1325,1329.[27]Zhang H,Niu Y,Gu H,et al.Low serum adiponectin is a predictor of progressing to nonalcoholic fatty liver disease[J].Journal of Clinical Laboratory Analysis,2018,33(6):e22709.[28]Qiu Y,Wang SF,Yu C,et al.Association of Circulating Adipsin, Visfatin, and Adiponectin with Nonalcoholic Fatty Liver Disease in Adults: A Case-Control Study[J].Annals of Nutrition and Metabolism,2019,74(1):44-52.[29]Feldman A,Eder SK,Felder TK,et al.Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver[J].Am J Gastroenterol,2017,112(1):102-110.[30]Borel AL,Nazare JA,Baillot A,et al.Cardiometabolic risk improvement in response to a 3-yr lifestyle modification program in men:contribution of improved cardiorespiratory fitness vs. weight loss[J].Am J Physiol Endocrinol Metab,2017,312(4):E273-E281.[31]Helfer G,Wu QF.Chemerin: a multifaceted adipokine involved in metabolic disorders[J].J Endocrinol,2018,238(2):R79-R94.[32]Ebert T,Gebhardt C,Scholz M,et al.Relationship Between 12 Adipocytokines and Distinct Components of the Metabolic Syndrome[J].J Clin Endocrinol Metab,2018,103(3):1015-1023.[33]张莉,高旭峰,王玉环.非酒精性脂肪肝并糖尿病前期chemerin表达及西格列汀对其表达的影响[J].中华医学杂志,2018,98(30):2407-2413.[34]Pohl R,Haberl EM,Rein-Fischboeck L,et al.Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis[J].Eur J Clin Invest,2017,47(1):7-18.[35]Horn P,von Loeffelholz C,Forkert F,et al.Low circulating chemerin levels correlate with hepatic dysfunction and increased mortality in decompensated liver cirrhosis[J].Sci Rep,2018,8(1):9242.[36]Fukuhara A,Matsuda M,Nishizawa M,et al.Visfatin: a protein secreted by visceral fat that mimics the effects of insulin[J].Science,2005,307(5708):426-430.[37]Amirkalali B,Sohrabi MR,Esrafily A,et al.Association between Nicotinamide Phosphoribosyltransferase and de novo Lipogenesis in Nonalcoholic Fatty Liver Disease[J].Med Princ Pract,2017,26(3):251-257.[38]Ismaiel A,Leucuta DC,Popa SL,et al.Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis[J].J Clin Med,2021,10(14):10143029.[39]郭娅棣,邓玉杰,孙洪林,等.非酒精性脂肪肝患者血清脂肪素、内脂素和鸢尾素水平及其相关性[J].实用医学杂志,2020,36(17):2376-2380.[40]杨丽,智深深.NAFLD患者血清CK-18、内脂素水平变化与纤维化指标的关系[J].河北医药,2019,41(11):1726-1728.[41]Hida K,Wada J,Eguchi J,et al.Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity[J].Proc Natl Acad Sci U S A,2005,102(30):10610-10615.[42]Waluga M,Kukla M,Zorniak M,et al.Vaspin mRNA levels in the liver of morbidly obese women with nonalcoholic fatty liver disease[J].Pol J Pathol,2017,68(2):128-137.[43]陈香梅,张亮,齐立明,等.脂肪因子Vaspin在非酒精性脂肪性肝病中的表达及其临床意义[J].中国现代医学杂志,2021,31(6):37-43.[44]苏秀丽,王同生,张英剑.血清脂肪因子网膜蛋白-1和内脏脂肪组织来源的丝氨酸蛋白酶抑制剂在非酒精性脂肪性肝病患者中的表达及意义[J].临床内科杂志,2021,38(2):94-96.[45]Huang SC,Yang YJ.Serum retinol-binding protein 4 is independently associated with pediatric NAFLD and fasting triglyceride level[J].J Pediatr Gastroenterol Nutr,2013,56(2):145-150.[46]Polyzos SA,Kountouras J,Polymerou V,et al.Vaspin, resistin, retinol-binding protein-4, interleukin-1alpha and interleukin-6 in patients with nonalcoholic fatty liver disease[J].Ann Hepatol,2016,15(5):705-714.[47]Chen X,Shen T,Li Q,et al.Retinol Binding Protein-4 Levels and Non-alcoholic Fatty Liver Disease: A community-based cross-sectional study[J].Sci Rep,2017,7:45100.[48]Lee SA,Yuen JJ,Jiang H,et al.Adipocyte-specific overexpression of retinol-binding protein 4 causes hepatic steatosis in mice[J].Hepatology,2016,64(5):1534-1546.[49]Montazerifar F,Bakhshipour AR,Karajibani M,et al.Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease[J].J Res Med Sci,2017,22:70.[50]Sanyal A,Charles ED,Neuschwander-Tetri BA,et al.Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial[J].Lancet,2019,392(10165):2705-2717.[51]Bao L,Yin J,Gao W,et al.A long‐acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non‐alcoholic steatohepatitis partly through an FGF21‐adiponectin‐IL17A pathway[J].British Journal of Pharmacology,2018,175(16):3379-3393.[52]Barb D,Bril F,Kalavalapalli S,et al.Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes[J].J Clin Endocrinol Metab,2019,104(8):3327-3336.[53]Shanaki M,Moradi N,Emamgholipour S,et al.Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes[J].Diabetes Metab Syndr,2017,11(Suppl 1):S467-S472.[54]Petta S,Valenti L,Svegliati-Baroni G,et al.Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease[J].J Clin Endocrinol Metab,2017,102(8):2660-2669.[55]Ajmera V,Perito ER,Bass NM,et al.Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease[J].Hepatology,2017,65(1):65-77.[56]张娴,陈宏.新型脂肪因子与肥胖相关代谢性疾病[J].国际内分泌代谢杂志,2018,38(3):171-175.[57]James OF,Day CP.Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance[J].Journal of Hepatology,1998,29(3):495-501.[58]王薇,史林平,石蕾,等.肠道益生菌辅助治疗非酒精性脂肪性肝病的临床研究[J].中华内科杂志,2018,57(2):101-106.[59]Leung C,Rivera L,Furness JB,et al.The role of the gut microbiota in NAFLD[J].Nature Reviews Gastroenterology & Hepatology,2016,53(6):412-425.[60]Liu Q,Niu C.From "two hit theory" to "multiple hit theory": Implications of evolution of pathogenesis concepts for treatment of non-alcoholic fatty liver disease[J].World Chinese Journal of Digestology,2019,27(19):1171-1178.[61]Maina V,Sutti S,Locatelli I,et al.Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice[J].Clinical Science,2012,122(11):545-553.[62]Rau M,Schilling AK,Meertens J,et al.Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver[J].Journal of Immunology,2016,196(1):97-105.[63]Lee Y,Hirose H,Ohneda M,et al.Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships[J].Proc Natl Acad Sci U S A,1994,91(23):10878-10882.